Quantum Genomics - Progress in heart failure and controlled release
Quantum Genomics recently announced that it has enrolled the first patient in the 294-patient Phase IIb QUORUM study of firibastat in heart failure. Separately, following a successful pharmacokinetic study, it has have selected a controlled release version of firibastat that will allow for once-a-day dosing (though the QUORUM study will still use the twice-a-day formulation). Successfully developing a once daily formulation should make the program more attractive to partners. As a reminder, the company is currently in discussions with a number of potential partners for the firibastat programme following the strong NEW-HOPE data.Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.